Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant.

Amat, P; Lopez-Corral, L; Goterris, R; Perez, A; Lopez, O; Heras, I; Arbona, C; Viguria, MC; Hernandez-Boluda, JC; Martinez-Ruiz, F; Martinez, A; Solano, C

Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant.

We conducted a multicenter interventional study to assess the efficacy of Therakos ECP to treat steroid-resistant graft-vs-host disease (SRes-GVHD) after allogeneic HSCT and to identify biomarkers of GVHD response. A total of 62 patients were treated for acute SRes-GVHD (n = 37) or chronic SRes-GVHD...

Descripción completa

Detalles Bibliográficos
Autores:	Amat, P, Lopez-Corral, L, Goterris, R, Perez, A, Lopez, O, Heras, I, Arbona, C, Viguria, MC, Hernandez-Boluda, JC, Martinez-Ruiz, F, Martinez, A, Solano, C
Tipo de recurso:	artículo
Estado:	Versión publicada
Fecha de publicación:	2021
País:	España
Institución:	INCLIVA
Repositorio:	r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:	oai:incliva.fundanetsuite.com:p15818
Acceso en línea:	https://incliva.portalinvestigacion.com/publicaciones/15818
Access Level:	acceso abierto
Palabra clave:	biomarkers extracorporeal photopheresis graft-vs-host disease steroid-refractory steroid-resistant

id	ES_9d2ac294f5fe2b73fc3ea7c1c7c07d8d
oai_identifier_str	oai:incliva.fundanetsuite.com:p15818
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant.Amat, PLopez-Corral, LGoterris, RPerez, ALopez, OHeras, IArbona, CViguria, MCHernandez-Boluda, JCMartinez-Ruiz, FMartinez, ASolano, Cbiomarkersextracorporeal photopheresisgraft-vs-host diseasesteroid-refractorysteroid-resistantWe conducted a multicenter interventional study to assess the efficacy of Therakos ECP to treat steroid-resistant graft-vs-host disease (SRes-GVHD) after allogeneic HSCT and to identify biomarkers of GVHD response. A total of 62 patients were treated for acute SRes-GVHD (n = 37) or chronic SRes-GVHD (n = 25). Median time to best response was 35 days (range, 28-85) and 90 days (range, 27-240) in acute and chronic SRes-GVHD, respectively. Overall, 27 patients (72.9%) with SRes-aGVHD responded to treatment (40.5% CR and 32.4% PR). The response rate was significantly higher in grade I-II than in grade III-IV aGVHD (100% vs 50.0%, respectively, P-value = .001). In chronic SRes-GVHD, 22 patients (88%) achieved a clinical response (24.0% CR and 64% PR). Response was higher in moderate than in severe SRes-cGVHD (100% vs 75%, P = .096). In both acute and chronic SRes-GVHD patients, the percentage of peripheral blood CD3(+) CD4(+) was higher and CD3(+) CD8(+) lower in responding than nonresponding patients. Acute SRes-GVHD responding patients presented a higher number of Treg cells (CD4(+) CD25(+) CD127(low/-) ) at day 0 (P = .028) than nonresponding patients, differences that were maintained over the observation period. Phenotypic analysis of T-cell maturation showed a trend toward reduction in TCD8 naive cells, along with an increased percentage of TCD8 Mem Efect T cells after starting ECP in responding patients. None of the studied serum cytokines displayed statistically significant changes in either acute or chronic SRes-GVHD. ECP is an effective treatment for patients with SRes-GVHD. Biomarkers could help guide decision-making on ECP treatment initiation and duration.WILEY2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/15818JOURNAL OF CLINICAL APHERESISISSN: 07332459ISSNe: 10981101reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p158182026-06-07T16:35:31Z
dc.title.none.fl_str_mv	Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant.
title	Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant.
spellingShingle	Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant. Amat, P biomarkers extracorporeal photopheresis graft-vs-host disease steroid-refractory steroid-resistant
title_short	Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant.
title_full	Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant.
title_fullStr	Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant.
title_full_unstemmed	Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant.
title_sort	Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant.
dc.creator.none.fl_str_mv	Amat, P Lopez-Corral, L Goterris, R Perez, A Lopez, O Heras, I Arbona, C Viguria, MC Hernandez-Boluda, JC Martinez-Ruiz, F Martinez, A Solano, C
author	Amat, P
author_facet	Amat, P Lopez-Corral, L Goterris, R Perez, A Lopez, O Heras, I Arbona, C Viguria, MC Hernandez-Boluda, JC Martinez-Ruiz, F Martinez, A Solano, C
author_role	author
author2	Lopez-Corral, L Goterris, R Perez, A Lopez, O Heras, I Arbona, C Viguria, MC Hernandez-Boluda, JC Martinez-Ruiz, F Martinez, A Solano, C
author2_role	author author author author author author author author author author author
dc.subject.none.fl_str_mv	biomarkers extracorporeal photopheresis graft-vs-host disease steroid-refractory steroid-resistant
topic	biomarkers extracorporeal photopheresis graft-vs-host disease steroid-refractory steroid-resistant
description	We conducted a multicenter interventional study to assess the efficacy of Therakos ECP to treat steroid-resistant graft-vs-host disease (SRes-GVHD) after allogeneic HSCT and to identify biomarkers of GVHD response. A total of 62 patients were treated for acute SRes-GVHD (n = 37) or chronic SRes-GVHD (n = 25). Median time to best response was 35 days (range, 28-85) and 90 days (range, 27-240) in acute and chronic SRes-GVHD, respectively. Overall, 27 patients (72.9%) with SRes-aGVHD responded to treatment (40.5% CR and 32.4% PR). The response rate was significantly higher in grade I-II than in grade III-IV aGVHD (100% vs 50.0%, respectively, P-value = .001). In chronic SRes-GVHD, 22 patients (88%) achieved a clinical response (24.0% CR and 64% PR). Response was higher in moderate than in severe SRes-cGVHD (100% vs 75%, P = .096). In both acute and chronic SRes-GVHD patients, the percentage of peripheral blood CD3(+) CD4(+) was higher and CD3(+) CD8(+) lower in responding than nonresponding patients. Acute SRes-GVHD responding patients presented a higher number of Treg cells (CD4(+) CD25(+) CD127(low/-) ) at day 0 (P = .028) than nonresponding patients, differences that were maintained over the observation period. Phenotypic analysis of T-cell maturation showed a trend toward reduction in TCD8 naive cells, along with an increased percentage of TCD8 Mem Efect T cells after starting ECP in responding patients. None of the studied serum cytokines displayed statistically significant changes in either acute or chronic SRes-GVHD. ECP is an effective treatment for patients with SRes-GVHD. Biomarkers could help guide decision-making on ECP treatment initiation and duration.
publishDate	2021
dc.date.none.fl_str_mv	2021
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	https://incliva.portalinvestigacion.com/publicaciones/15818
url	https://incliva.portalinvestigacion.com/publicaciones/15818
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	WILEY
publisher.none.fl_str_mv	WILEY
dc.source.none.fl_str_mv	JOURNAL OF CLINICAL APHERESIS ISSN: 07332459 ISSNe: 10981101 reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname:INCLIVA
instname_str	INCLIVA
reponame_str	r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection	r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869414719703482368
score	15,811543

Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant.

Similares en LA Referencia